-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-510278-14-00
5
2022-06-16
Niemann-Pick disease type C
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-508532-56-00
5
2021-10-19
Treatment with a Vitamin K Antagonist due to having a mechanical bilea
-
2024-511246-39-00
1
2021-07-27
Solid tumours with HER2 aberrations
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-516741-39-00
6
2020-01-14
Haemophilia A
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD
-
2025-521970-33-00
5
2025-12-19
Pulmonary Arterial Hypertension (PAH)
-
2024-512914-16-00
5
2025-09-12
Relapsing-remitting Multiple Sclerosis
-
2024-519011-34-00
3
2025-08-04
Urinary Tract Infection
-
2024-516473-72-00
5
2025-07-31
Multifocal Motor Neuropathy
-
2024-511754-41-00
4
2025-05-29
idiopathic pulmonary fibrosis
-
2024-515773-99-00
4
2025-05-26
Pulmonary Hypertension
-
2024-514064-17-00
3
2025-05-23
Pulmonary Arterial Hypertension